Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease
about
Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval PathwayEffects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial.Controversies in the Diagnosis and Management of NAFLD and NASH.Current status and agenda in the diagnosis of nonalcoholic steatohepatitis in JapanDiagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysisA Relative Deficiency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver DiseaseEstablishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology.Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis.Hepatic crown-like structure: a unique histological feature in non-alcoholic steatohepatitis in mice and humansMelanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis.Eicosapentaenoic acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient miceDifferential Immunometabolic Phenotype in Th1 and Th2 Dominant Mouse Strains in Response to High-Fat Feeding.Is Assessing the Presence of NASH by Liver Histology or Surrogate Markers Always Advisable?Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitisEvaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication.Rimonabant Improves Oxidative/Nitrosative Stress in Mice with Nonalcoholic Fatty Liver Disease.Inter-observer and Intra-observer Agreement in Pathological Evaluation of Non-alcoholic Fatty Liver Disease Suspected Liver BiopsiesSerum biomarkers in type 2 diabetic patients with non-alcoholic steatohepatitis and advanced fibrosis.The fat droplet in hepatocellular ballooning and implications for scoring nonalcoholic steatohepatitis therapeutic response.Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.Controlled attenuation parameter is correlated with actual hepatic fat content in patients with non-alcoholic fatty liver disease with none-to-mild obesity and liver fibrosis.Comparison of conventional sonographic signs and magnetic resonance imaging proton density fat fraction for assessment of hepatic steatosis.Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation.Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease.
P2860
Q26800894-FC94E70B-A2A1-4B94-997A-A5FEEA6E5A94Q30361789-0B5F9D25-D540-45F1-A02E-7E03D55776EDQ30412296-E4A8E5C3-7FE6-44BD-AAAC-2D15E6FCAF30Q30478139-C557E39A-3D16-4752-AA93-E6D917F5566FQ30592294-6223F03A-4AD9-4CF8-8BE5-1255170A7C69Q33838454-878DA5E0-D7A7-49D7-B338-2CDDC45AFD11Q34764818-F26A94E9-6765-4EDC-A609-5F21C53E8113Q34785324-9275A44C-198C-4D84-B3A7-DA48003BFB39Q35070019-1150514F-D295-43EF-9171-264D1E0B396BQ35474335-2436A007-1857-4114-96ED-99BB9F91228CQ35588868-2F871005-4306-4965-89B4-AAC898F54A00Q35720450-2699BA58-370A-478D-978B-96AD23254418Q36781591-51403559-67C7-4067-9F29-0E01E8F40543Q37581357-DF6896F9-1622-4C7F-8391-D67A31FE2BFFQ38183450-3B657E18-8E36-452C-854A-0FEE7F9FBD9AQ41008505-884EC52D-79A5-4588-B213-71397BC50BF2Q41783506-A63AB6B7-A8A8-4867-BE2F-B212198485ECQ43960965-3D72100C-594F-4092-B57C-09302CC27E3FQ45016752-63C568A0-E6F5-4704-9A25-747A5272A00EQ46628692-BDB1CF08-94E9-4DA0-96B6-C496223CFC42Q47136445-7C1A1EA8-30CE-4E67-AC4C-473674BADF83Q53914539-A6479E71-D27F-490E-9690-3B90B2979F07Q55027170-6D32EC8B-0D7E-4BE3-A43D-1D2D6305CFABQ55122484-978FBE07-B2C2-47B1-9D8B-C34D46BA7947Q55278681-F581987E-E309-4FCC-B982-60EE2E27B8B1Q55490768-058298D2-1AED-4FB1-9C6F-3EF77F2026D1
P2860
Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Generalizability of the nonalc ...... nalcoholic fatty liver disease
@ast
Generalizability of the nonalc ...... nalcoholic fatty liver disease
@en
Generalizability of the nonalc ...... nalcoholic fatty liver disease
@nl
type
label
Generalizability of the nonalc ...... nalcoholic fatty liver disease
@ast
Generalizability of the nonalc ...... nalcoholic fatty liver disease
@en
Generalizability of the nonalc ...... nalcoholic fatty liver disease
@nl
prefLabel
Generalizability of the nonalc ...... nalcoholic fatty liver disease
@ast
Generalizability of the nonalc ...... nalcoholic fatty liver disease
@en
Generalizability of the nonalc ...... nalcoholic fatty liver disease
@nl
P2093
P2860
P1476
Generalizability of the nonalc ...... nalcoholic fatty liver disease
@en
P2093
Aynur Unalp
James Tonascia
John Olson
Mark L Van Natta
Naga Chalasani
Oscar W Cummings
Ravi Juluri
P2860
P356
10.1097/MCG.0B013E3181DD1348
P577
2011-01-01T00:00:00Z